OAB & the Microbiome

Clinical Trial Summary

To determine differences in the urinary microbiomes, identified by polymerase change reaction (PCR) (UTIP™), of female patients with urgency and frequency syndrome with or without pelvic pain (Group A) compared to female controls without symptoms of lower urinary tract symptoms (LUTS) (Group B).

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04578899` - "The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"	N/A
Active, not recruiting	`NCT03556891` - Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence	N/A
Not yet recruiting	`NCT05977634` - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder	N/A
Completed	`NCT01955408` - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment	N/A
Recruiting	`NCT06201013` - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children	N/A
Recruiting	`NCT03727711` - TPTNS: Home vs Hospital Treatment for Overactive Bladder	N/A
Completed	`NCT00768521` - A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)	Phase 1
Completed	`NCT03625843` - Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing	N/A
Completed	`NCT02211846` - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder	Phase 1
Completed	`NCT02857816` - PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB	N/A
Completed	`NCT02835846` - Investigation of the Effect of the Female Urinary Microbiome on Incontinence	Phase 4
Withdrawn	`NCT02320201` - Foot Neuromodulation for Overactive Bladder in Children	N/A
Completed	`NCT02202031` - Controlling Urgency Through Relaxation Exercises	N/A
Completed	`NCT01458197` - A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.	Phase 2
Not yet recruiting	`NCT01409512` - Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder	N/A
Completed	`NCT01437670` - Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin	N/A
Not yet recruiting	`NCT01423838` - Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder	Phase 4
Terminated	`NCT01758848` - Physical Therapy for Overactive Bladder	N/A
Withdrawn	`NCT01210859` - Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents	N/A
Terminated	`NCT01003249` - Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen	Phase 4

NCT number	NCT04831801
Study type	Observational
Source	University of Miami
Contact
Status	Terminated
Phase
Start date	June 30, 2021
Completion date	November 20, 2023

OAB and the Microbiome

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms